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Abstract
Since 1980, the global prevalence of obesity has doubled; in the United States, it has almost tripled. Billions of people are
overweight and obese; the WHO reports that >65% of the worlds population die of diseases related to overweight rather
than underweight. Obesity is a complex disease that can be studied from ‘‘metropolis tometabolite’’—that is, beginning at
the policy and the population level through epidemiology and intervention studies; to bench work including preclinical
models, tissue, and cell culture studies; to biochemical assays; and to metabolomics. Metabolomics is the next research
frontier because it provides a real-time snapshot of biochemical building blocks and products of cellular processes. This
report comments on practical considerations when conducting metabolomics research. The pros and cons and important study
design concerns are addressed to aid in increasingmetabolomics research in the United States. The link betweenmetabolism and
inflammation is an understudied phenomenon that has great potential to transform our understanding of immunometabolism in
obesity, diabetes, cancer, and other diseases; metabolomics promises to be an important tool in understanding the complex
relations between factors contributing to such diseases. J Nutr 2015;145:1131S–6S.
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Obesity and Inflammation
Over the past 30 y, the prevalence of obesity has increased
epidemically in both Western nations and in developing coun-
tries, with little hope for effective treatments on the horizon (1,
2). More than one-third of adults and almost 1 in 5 children in
the United States are obese. Globally, the WHO estimates that
500 million adults and almost 43 million children <5 y are obese
(3). Childhood obesity is of particular concern because health
care professionals are increasingly treating children for condi-
tions that were traditionally considered to be adult diseases such
as type 2 diabetes, high blood pressure, insulin resistance, and
dyslipidemia (4, 5).
Importantly, obesity is a preventable disease. In the United
States, the American Medical Association recently classified
obesity as a disease (6). There are various complications
associated with obesity, including coronary artery disease, type 2
diabetes, certain cancers (7), hypertension, dyslipidemia, stroke,
liver and gallbladder disease, sleep apnea and respiratory
problems, osteoarthritis, and gynecologic disorders such as
abnormal menses and infertility. The underlying causes of
obesity represent a complex web of interactions including
inherited genetic traits, low physical activity levels, environ-
mental factors such as access to affordable healthy food, cultural
identity, socioeconomic status, and others.
At the cellular level, work over the past decade has
increasingly linked obesity and inflammation (2). It has been
demonstrated that immune cells infiltrate adipose tissue at the
onset of weight gain and directly contribute to and perpetuate
the inflammatory state of fat, systemic insulin resistance, and
the promotion of obesity (8–14). One inflammatory cell, the
macrophage, accumulates in obese adipose tissue and quantities
directly correlate with adipocyte size, age, female sex, and
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numerous inflammatory mediators (15). Clear associations
exist between obesity, metabolic syndrome, and macrophage-
mediated inflammation (16). Classically activated macrophages
infiltrate adipose tissue at the onset of weight gain, and
contribute to the chronically inflamed state that leads to insulin
resistance and diabetes. In contrast, alternatively activated
macrophages safeguard insulin sensitivity and tissue homeosta-
sis in metabolically active tissues (2). Many questions remain
about how macrophage phenotypes are regulated within the
adipose microenvironment along the classical-alternative polar-
ization spectrum. Our group focuses on the relation between the
tissue microenvironment and macrophage metabolism in regu-
lating obesity-associated inflammation in diseases such as
diabetes, atherosclerosis, and breast and ovarian cancers. This
review focuses on the preclinical and clinical considerations of
using metabolomics as a tool to aid in understanding how
metabolism regulates the inflammatory response.
How Is Obesity Studied?
Preclinical models are commonly used to mimic human obesity,
albeit with the understanding that mice do not always perfectly
model human physiology. There are 2 methods for modeling
obesity in preclinical rodent-based systems: by using genetic
manipulation approaches, such as gene mutation or over-
expression, or by using custom diets to induce obesity. The first
knockout mouse model was created in 1989 (17). Since then, the
use of genetic models in the laboratory where a single gene is
deleted or overexpressed is a common method that is widely
used for modeling and understanding the etiology and progres-
sion of an array of diseases, including obesity. Various model
systems have been developed that are aimed at studying the
underlying biochemical mechanisms that play a role in the onset
and progression of obesity, as well as the metabolic pathologies
associated with obesity. Existing mouse models are available
through companies such as The Jackson Laboratory or Charles
River Laboratories, or models can be made in the laboratory or
at many mouse core facilities at most research institutes.
Examples of genetic models of obesity include ob/ob mice,
which lack leptin; db/dbmice, which lack leptin receptor; Agouti
yellow mice; melanocortin 4 receptor–deficient mice; and
Zucker fa/fa obese rats. Such monogenic approaches have
proven to be powerful tools providing abundant information
into the contribution of single pathways to obesity. However,
they are limited in terms of how this information can be
translated to the condition of human obesity because it is
exceedingly rare that humans have a single gene mutation that
leads to obesity (18). The reality is that obesity is a complex
genetic disorder involving multiple single nucleotide polymor-
phisms, epigenetic patterns, and multiple, cumulative exposures
beginning in utero and continuing over an entire life span. The
environmental exposures at play include physical activity,
environmental chemicals, our microbiome, and importantly,
our diet—all of which contribute to obesity onset, progression,
and severity.
Although rodent genetic models of obesity have provided
valuable insight into the biochemical underpinnings of obesity,
for the reasons discussed above diet-induced obesity (DIO6)
models more accurately represent obesity observed in humans.
Thus, the use of animal models exposed to obesogenic diets best
model the human condition (19). There are many diets that
cause obesity. Rodents readily consume high-fat diets and can be
weaned onto these diets. Obesity onset is usually rapid, with
significant weight gain observed within weeks to a few months
from the initiation of the diet. DIO experiments can be
extremely well controlled due to the ability to use littermates,
which ensures that study animals are genetically identical and
exposed to similar in utero, maternal, and home cage environ-
ments.
Humans consume, on average, 34–45% of energy from fat
(20), which must be taken into consideration in the laboratory
setting, where scientists aim for the most human-relevant high-
fat intake through DIO models. There are several DIO diets that
are regularly used, each with its own set of advantages and
shortcomings; however, first, it is important to understand
unpurified diets, especially when considering the most appro-
priate ‘‘control’’ for the DIO diet to be used. Rodents in animal
facilities are commonly maintained on a feed pellet diet,
consisting of ground oats, barley, wheat, and corn (a diet high
in fiber and phytoestrogens). Importantly, unpurified diets are
undefined, and although the composition of macro- and micro-
nutrients in unpurified diets is always constant, the source of
those nutrients can vary from lot to lot. Recognizing this fact is
important when analyzing and interpreting DIO model data if
unpurified diets are chosen as the ‘‘control’’ diet.
Purified or defined diets are diets that are mass produced by
companies wherein all diet components are known. Choline-
deficient and methyl-donor–deficient diets, which lack choline,
folate, and methionine, or high-sucrose diets are 3 obesogenic
diets that can be used in DIO studies. However, by far the most
commonly used diets are the high-fat diets. The most widely
used diet is a lard-based van Heek series, which includes a range
of high-fat diets with 45% or 60% of energy derived from fat,
typically lard; therefore, these diets have a high saturated fat
content. They are commonly paired with a diet with 10% of
energy derived from fat (a ‘‘low fat’’ control diet) that does not
induce obesity. The pitfall with this 10% control diet is that to be
isocaloric to the high-fat diets that contain 45% or 60% of
energy from fat, the diet containing 10% of energy from fat is
usually high in sucrose, which can induce fatty liver. Another
alternative diet is the Western diet, which also derives its fat
from lard, as with the van Heek series, and contains added
cholesterol to induce atherosclerosis. In addition, specialized
diets are available, including the Surwit diet which is high in
coconut oil (medium-chain fats), for specific scientific questions.
As discussed above, a complicating factor for many of these diets
is that to remain isocaloric, sucrose is added to the low-fat diet to
match the caloric content of the high-fat diet. Sucrose is a
combination of glucose and fructose, which can induce weight
gain through multiple pathways (21), although to a lesser extent
than high-fat diets. To overcome this limitation, sucrose-free
diets are available in which sucrose has been replaced with a
more complex carbohydrate such as cornstarch.
Finally, the diet model that may best mimic human obesity is
called the Cafeteria (CAF) diet. The CAF diet is a labor-intensive
smorgasbord feeding model in which rodents are provided the
choice of unpurified diets or highly palatable, calorically dense,
nutrient-deficient human ‘‘junk’’ foods purchased from a grocery
store. Therefore, the food exposure more closely parallels what
humans are eating. Indeed, Piernas et al. (22) reported that in
preschool-aged kids, snack foods account for 27% of total
caloric intake. Why is this important? Snack foods are energy
dense, providing lots of calories with little nutritional value. For
6 Abbreviations used: CAF, Cafeteria; DIO, diet-induced obesity; FABP4, fatty
acid binding protein aP2; GLUT1, glucose transporter 1; IkK, inhibitor of kappa B
kinase; RTP, Research Triangle Park, NC.
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example, 100 g of fresh corn has 83 kcal, a corn tortilla contains
210 kcal, and fully processed, energy-dense tortilla chips contain
493 kcal per serving.
Our laboratory was interested in comparing the obesogenic
and inflammatory effect of various diets including the CAF diet.
We provided a choice of 3 human foods that varied from day to
day, including cookies, salami, chips, chocolate, muffins, cereals,
and cheese, among other options. Detailed information on the
diets is available in Sampey et al. (21, 23). Although rats fed this
junk-food diet ate;17% of calories from feed pellets, overall we
observed hyperphagia resulting in rapid weight gain in the CAF
diet–fed rats above and beyond what we observed in the rats fed
diets that contained 45% of energy from fat and 10% of energy
from fat and an unpurified diet–only control diet. Rats fed the
control diets consumed ;100 kcal/d, whereas rats fed the CAF
diet consumed 130–150 kcal/d (21). The CAF diet is a model to
broadly mimic human snacking, because a variety of options and
the palatability of snack foods lead to overeating (21). CAF diet–
fed rats developed prediabetes characterized by elevated insulin,
fasting blood glucose, and circulating nonesterified FFAs, with
concurrent impaired glucose and insulin tolerance. Both the liver
and adipose tissue from CAF diet–fed rats were severely inflamed,
and markers of pancreatic islet dysfunction were evident. Of note,
when we compared rats fed the low-fat (10% of energy from fat)
and high-fat (45% of energy from fat)–defined diets, we did not
see significant divergence between the groups at the same time
point at which we saw dramatic CAF diet–induced metabolic
dysfunction. Given the remarkable effects of the CAF diet, we
turned to metabolomics to provide insight into why the CAF
diet induced inflammation that was much more severe than the
typical 45% high-fat experimental diet. Using metabolomics
and bioinformatics analysis, we identified mitochondrial dys-
function and a specific acylcarnitine, lauroylcarnitine, a me-
tabolite of FA oxidation that was elevated in adipose tissue of
CAF diet–fed rats compared with high-fat-diet–fed or control
rats (21, 23). Lauroylcarnitine significantly correlated with
crown-like structures in adipose tissue, markers of inflammation
and insulin resistance. We then demonstrated that lauroylcarni-
tine drove proinflammatory macrophage polarization and cyto-
kine release, therefore providing a potential mechanism linking
obesity, lipid metabolism, and inflammation to be tested in future
studies (21, 23).
How Does a Molecular Biologist
Incorporate Metabolomics into Nutrition
Research?
Substantial progress has been made in understanding the
inflammatory phenotype of macrophages in the microenviron-
ment of tissues such as adipose, liver, and the vessel wall in
atherosclerosis. However, how metabolism regulates macro-
phage polarization, thus influencing tissue inflammation and
insulin resistance within metabolically active tissue microenvi-
ronments, is poorly understood (2). Addressing this question is
essential because cellular and molecular pathways regulated by
metabolites, such as bioactive lipid mediators, have yet to be
explored in great detail and will have tremendous potential as
novel therapeutic targets. The ability to harness control of the
‘‘immune-metabolic’’ milieu could break the proinflammatory
cycle and would control insulin resistance, compensatory
hyperinsulinemia, and hyperglycemia of diabetes. Our previous
work on cytosolic FA binding protein aP2 (FABP4) lends support
to the concept of fuel metabolism and inflammation being
interdependent; we demonstrated that the integration of lipid
trafficking and signaling in the macrophage contributes signif-
icantly to the pathogenesis of atherosclerosis, insulin resistance,
and obesity through multiple pathways such as the nuclear
hormone receptor PPAR-g, modulation of reverse cholesterol
transport, the inflammatory inhibitor of kappa B kinase (Ikk)–
NF-kB kinase pathway, and endoplasmic reticulum stress (2, 21,
23–33). Furthermore, Vats et al. (34) established that generation
of alternatively activated macrophages is an FA oxidation-
dependent process. We recently demonstrated that metabolic
reprogramming of macrophages is possible in vitro through
overexpressing glucose transporter 1 (GLUT1) (35). Using
metabolomics, we showed that forced glucose metabolism and
activation of the pentose phosphate pathway was sufficient to
polarize macrophages to the classically activated macrophage
phenotype (35). Therefore, an important modifier of macro-
phage plasticity and the inflammatory tone contributing to the
onset of diabetes is the availability of fuel substrates to the
macrophages in the microenvironment. Biochemists recognize
that glucose- and lipid-involving metabolic pathways, in fact all
metabolic pathways, work in concert to maintain cellular and
tissue homeostasis. Therefore, altering some aspect of glucose
metabolism, for example, will undoubtedly have effects on lipid
and protein metabolic pathways. Classic radiotracer methods
are useful for determining flux through a specific pathway,
but to get at the heart of how a cell or tissue is responding to a
metabolic change in a more holistic way, metabolomics can
be used.
What Are the Options for Metabolomics
for Clinicians or Bench Scientists?
As biochemists who want to understand the metabolic under-
pinnings of processes but do not have the chemistry, informatics,
or programming background to answer such questions alone, we
have to turn to others to conduct metabolomics analyses (Figure 1).
When designing a metabolomics study, one must carefully
consider the hypothesis to be tested or question asked while at
the same time designing studies that are sufficiently powered to
detect differences considering the expected biological variation
and keeping within budgetary constraints. One may conduct
targeted investigations to detect a few important metabolites
or run samples through multiple platforms in an unbiased
discovery-based approach. As with other technologies, cell
culture studies are inherently less variable than mouse samples,
which are, in turn, less variable than human samples. Control-
ling for as many variables as possible is imperative. In our
experience, 50–200 mg for most tissues, 50–100 mL of plasma,
or;1 million cells are sufficient for most metabolomics analyses
(23, 24, 35–37). Sample size should be as great as possible
because multiple metabolites are measured, which is similar to a
microarray study. Clinical considerations include sample size
and proper controls as in any study; however, one must consider
the metabolic state of patients (fasted, taking medications, etc.)
and the time to capture the sample from the operating room or
clinic to the freezer. Some studies use a ‘‘stop watch’’ approach
and place a stop watch with the sample when the clinician
isolates it. The stop watch only gets turned off when the sample
is frozen in liquid nitrogen. Depending on the isolation of the
sample, availability of the research associate, and transport to
the laboratory, sample freezing times can vary from minutes to
many hours. This is highly relevant when analyzing metabolites.
Furthermore, because clinical samples are precious, it is best to
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optimize on practice samples. Finally, a benefit of using
metabolomics rather than other biomarkers (e.g., serum or
urine proteins such as a cytokine) is that metabolites do not vary
by species. There can be extensive cross-species validation.
There are several approaches for initiating metabolomics
research—with pros and cons for each—and every laboratory
must decide what fits best. First, for those ‘‘do it yourself-ers’’
with the proper machinery and training, metabolomics is a
matter of having the right authentic standards to quantitate
specific metabolites of interest and the right people to prepare
samples and operate your machines. One caveat to conducting
your own metabolomics is that it is often cost-prohibitive to
purchase the hundreds of authentic standards necessary to
conduct comprehensive discovery work. Furthermore, without
the proper training in programming and statistics, one is often
left ‘‘eye-balling’’ the data for significant findings. Of course,
there are plenty of outstanding researchers who have excellent
metabolomics facilities. Collaborating with such experts is the
second route to pursue metabolomics research as a novice.
As with any collaboration, there are pluses and minuses: one
must discuss costs, personnel, and authorship upfront. A typical
hurdle with collaborations is the timeline for study completion
TABLE 1 Location and representative publications for sites conducting metabolomic analysis1
Commercial sites for metabolomic analysis
Name Location URL Representative publications
Metabolon, Inc. Durham, NC (RTP) www.metabolon.com (23, 36, 38)
Lipomics, Inc. (owned by Metabolon, Inc.) Sacramento, CA www.lipomics.com (24)
Metabolomic Discoveries Potsdam-Golm, Germany www.metabolomicdiscoveries.com (39, 40)
Chenomx, Inc. Edmonton, Canada www.chenomx.com (41, 42)
RCMRCs, NIH-funded and Common Funds Metabolomics program
NIH West Coast Metabolomics Center at UC Davis (WC3MRC) Davis, CA www.metabolomics.ucdavis.edu (43, 44)
Michigan Regional Comprehensive Metabolomics Research
Core (MRC)
Ann Arbor, MI www.mrc2.umich.edu (45, 46)
NIH Eastern Regional Comprehensive Metabolomics Resource
Core at RTI International (RTI RCMRC)
Durham (RTP), NC www.rti.org (47, 48)
Southeast Center for Integrated Metabolomics at University of
Florida (SECIM)
Gainesville, FL www.secim.ufl.edu (49, 50)
Resource Center for Stable Isotope–Resolved Metabolomics at
University of Kentucky (RC-SIRM)
Lexington, KY www.bioinformatics.cesb.uky.edu (49, 50)
Metabolomics Resource Core at the Mayo Clinic Rochester, MN www.mayo.edu (51, 52)
1 RCMRC, Regional Comprehensive Metabolomics Research Core; RTP, Research Triangle Park, NC.
FIGURE 1 The pros and
cons of metabolomics.
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and the possible extended wait time for your samples to be
analyzed. However, working closely with experts will help with
experimental design, data interpretation, and planning of
further experiments. Collaborating with a company that con-
ducts metabolomics is also an option, but that has drawbacks as
well, such as access (because not every company will want to
collaborate with you) and intellectual property concerns. For
example, the method of processing samples used may be
proprietary and there may be substantial hurdles to clear when
it is time to publish.
The third option is a fee-for-service through companies that
specialize in metabolomics such as Metabolon, Lipomics
(recently acquired by Metabolon), Metabolomic Discoveries,
and Chenomx, among others (Table 1). There can be substantial
costs associated with this approach depending on the service
package purchased; services offered can range from study design
and sample prep to statistical analysis, data interpretation, and
figure preparation. Through their high-throughput capacity
and standard operating procedures, companies often will have
established protocols for your samples, including quantities
necessary, tricks for preparing samples, etc., that save time and
money because assay optimizations are not necessary. Because it
is a fee-for-service rather than a collaboration, data are usually
generated within an established time as agreed upon when a
contract is signed. Companies must consider customer satisfac-
tion and repeat business, but this is a relationship that you pay
for. Although you are guaranteed a final product, the option to
go back and conduct follow-up experiments is not possible
without acquiring additional costs.
A fourth and final metabolomics option is a new initiative
supported by the NIH funded through the Common Funds
Metabolomics program (Table 1). This is a national program
aimed at increasing metabolomics capacity by developing
centers with high-throughput technologies, training, and men-
toring for metabolomics researchers. The goal is to standardize
protocols in an effort to increase sensitivity and speed to identify
metabolites. In addition, by providing reference standards and
data sharing, the NIH hopes to build a publicly accessible
national database that will propel metabolomics research
forward. There are currently 6 Regional Comprehensive
Metabolomics Research Cores (RCMRCs) funded by the
Metabolomics program. The cores have expertise, instruments,
and training programs to increase metabolomics capacity.
Existing sites are as follows: 1) NIH West Coast Metabolomics
Center at UC Davis (WC3MRC), 2) Michigan Regional Com-
prehensive Metabolomics Research Core (MRC), 3) NIH
Eastern Regional Comprehensive Metabolomics Resource
Core at RTI International (RTI RCMRC), 4) Southeast Center
for Integrated Metabolomics (SECIM), 5) Resource Center for
Stable Isotope-Resolved Metabolomics (RC-SIRM), and 6) the
Metabolomics Core at the Mayo Clinic.
Importantly, with strong bioinformatics support, ‘‘omics’’-
based approaches can be used for hypothesis generating,
biomarker identification, and, ideally, lead to biomarkers in
vivo or in vitro to be tested as bona fide biomediators of
observed effects. In summary, the link between metabolism and
inflammation is an understudied phenomenon that has great
potential to transform our understanding of immunometabolism
in obesity, diabetes, cancer, and other diseases. One important
benefit of metabolomics is that metabolites are conserved across
species, as mentioned above, which makes it easy to translate
preclinical findings to humans. Bioinformatics approaches
provide a deeper understanding of the complex relations
between these pathways that would otherwise be impossible
with traditional biochemical assays. Current and future students
and postdoctoral fellows should be encouraged to incorporate
statistical training, computer programming, and informatics
into their education in conjunction with basic molecular biology
techniques and a strong understanding of metabolism to best be
prepared for the next era of high-density, high-throughput data
generation using metabolomics.
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